Corporate | 3 November 2015 11:40
DGAP-News: Evotec AG / Key word(s): Miscellaneous
2015-11-03 / 11:40
---------------------------------------------------------------------
Hamburg, Germany - 03 November 2015: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) will report its financial results for the
first nine months of 2015 on Tuesday, 10 November 2015.
The Company is going to hold a conference call to discuss the results as
well as to provide an update on its performance. The conference will be
held in English.
Conference call details
Date: Tuesday, 10 November 2015
Time: 02.00 pm CET (01.00 pm GMT, 08.00 am EST)
From Germany: +49 (0) 69 22 22 29 043
From UK: +44 20 30092452
From USA: +1 855 4027766
From France: +33 170 750705
Access Code: 37969784#
A simultaneous slide presentation for participants dialling in via phone is
available at http://www.audio-webcast.com/ password: evotec1115.
Webcast details
To join the audio webcast and to access the presentation slides you will
find a link on our home page www.evotec.com shortly before the event.
A replay of the conference call will be available for 24 hours and can be
accessed in Europe by dialling +49 69 22 22 33 985 (Germany) or +44 20 3426
2807 (UK) and in the US by dialling +1 866 535 8030. The access code is
654573#. The on-demand version of the webcast will be available on our
website:
http://www.evotec.com/article/en/Investors/Finance/Financial-Reports-2013-
2015/188/6/26.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
---------------------------------------------------------------------
2015-11-03 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of News DGAP News Service
---------------------------------------------------------------------
408019 2015-11-03